Hope for rhabdomyosarcoma: vitamin a derivative joins chemo in new trial
NCT ID NCT07355855
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding all-trans retinoic acid (a vitamin A derivative) to standard VAC chemotherapy improves outcomes for 106 people aged 14-60 with intermediate-to-high-risk rhabdomyosarcoma, a rare muscle cancer. Participants will receive the drug combo in 21-day cycles, and researchers will track survival, tumor response, and side effects. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- all-trans retinoic acid (ATRA) combined with VAC chemotherapy (vincristine, dactinomycin, cyclophosphamide)
- What this could lead to
- If this works, it could improve survival and disease control for people with intermediate-to-high-risk rhabdomyosarcoma, offering a more effective treatment option.
- What could go wrong
- This is an early Phase 2 trial with only 106 participants, so results may not apply to everyone. The combination may cause side effects like those from standard chemotherapy, and it is not yet proven to be better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHABDOMYOSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan university cancer hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can engineered immune cells tackle childhood sarcoma?
- Can AI read tumor slides to outsmart childhood cancer?
- Ultrasound, CT, and MRI put to the test for identifying childhood neck lumps
- Combination drug approach aims to tackle tough childhood cancer
- Targeted radiation zaps childhood brain tumors in early trial
- New drug combo aims to beat tough childhood cancer